On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > REGULATORY
REGULATORY
- Chuikyo’s Draft Supplementary Opinions for 2020 Reimbursement Reform Calls for Medical Validity, Cost-Effective Analysis for Prescriptions
February 3, 2020
- Takeda’s RCC Drug Cabometyx Now in Line for March Approval; Alecensa, Rozlytrek Opdivo and More
January 30, 2020
- MHLW to Incentivize Physicians to Use Biosimilars with New Premium
January 30, 2020
- Sanofi to Temporarily Stop Taking Orders for ActHIB due to “Multiple Cases” of Rust Found in Needles: MHLW
January 30, 2020
- Japan Ups Responses against Wuhan Coronavirus as First Domestic Transmission Confirmed
January 29, 2020
- MHLW Panel Gives Thumbs Up for Novartis’ ADM Med Brolucizumab for Approval in as Early as March
January 29, 2020
- Discussions on Off-Year Re-Pricing to Begin in Spring, Focus on Scope of Drugs, Impact on Stakeholders: MHLW Bureau Chief
January 27, 2020
- ICH’s Guidelines Helped Bring NDMA Contamination Problem to Light: NIHS Officials
January 24, 2020
- Japan Approved World’s 1st Topical JAK Inhibitor Delgocitinib, and More
January 24, 2020
- PMDA to Provide Information Free of Charge for Drug Makers to Consider Use of MID-NET Starting in April
January 24, 2020
- Chuikyo OKs New Drug Pricing Rules for 2020 Reform
January 23, 2020
- Nasal Steroid Used as “Reference Drug” for Xolair in Special Re-Pricing
January 23, 2020
- Get Serious about Reviewing Scope of Health Coverage, Says MOF Budget Examiner
January 22, 2020
- Japan’s Special Re-Pricing Rules to Hit 17 Drugs in April; Potentially Big Slash for Keytruda, Lixiana
January 22, 2020
- MHLW Orders Label Revisions for Suglat, Sujanu, and More
January 22, 2020
- Xolair Faces New Special Re-Pricing Rule; Keytruda, Lixiana Caught by Huge-Seller Price Slash
January 21, 2020
- MHLW Bureau Chief Urges Prefectural Officials to Up Monitoring Efforts after GMP Lapses Found
January 21, 2020
- MHLW Bureau Chief Says Delay Would Be Inevitable to Revise Drug Distribution Guidelines as Bid-Rigging Probe Continues
January 17, 2020
- Takeda’s RCC Drug Cabometyx in MHLW Panel’s Review Roster for January 29; Alecensa, Opdivo and More
January 16, 2020
- Japan Forgoes Creation of Medical Fee to Reward Hospital Formularies in 2020 Reform
January 16, 2020
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…